Syndax Pharmaceuticals Elects New Director
Ticker: SNDX · Form: 8-K · Filed: May 16, 2025 · CIK: 1395937
| Field | Detail |
|---|---|
| Company | Syndax Pharmaceuticals Inc (SNDX) |
| Form Type | 8-K |
| Filed Date | May 16, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-of-directors, governance
Related Tickers: SNDX
TL;DR
Syndax adds Dr. Michael S. Brown to its board, effective May 12, 2025.
AI Summary
Syndax Pharmaceuticals, Inc. announced on May 12, 2025, a change in its board of directors. Specifically, Dr. Michael S. Brown has been elected as a Class II Director, effective immediately. This appointment is part of the company's ongoing governance and strategic direction.
Why It Matters
The election of a new director can signal shifts in company strategy or governance, potentially impacting future decisions and shareholder value.
Risk Assessment
Risk Level: low — The filing reports a routine board appointment, which typically carries low immediate risk.
Key Players & Entities
- Syndax Pharmaceuticals, Inc. (company) — Registrant
- Dr. Michael S. Brown (person) — Newly elected Class II Director
- May 12, 2025 (date) — Effective date of director election
FAQ
Who has been elected as a Class II Director at Syndax Pharmaceuticals?
Dr. Michael S. Brown has been elected as a Class II Director.
When was the election of Dr. Michael S. Brown effective?
The election was effective as of May 12, 2025.
What is the filing date for this 8-K report?
The filing date is May 16, 2025.
What is the exact name of the Registrant?
The exact name of the Registrant is Syndax Pharmaceuticals, Inc.
What is the Commission File Number for Syndax Pharmaceuticals?
The Commission File Number is 001-37708.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 16, 2025 by Dr. Michael S. Brown regarding Syndax Pharmaceuticals Inc (SNDX).